Effectiveness of Dipeptide N (2)-L-Alanyl-L-Glutamine in Trauma ICU Patients: Pilot, Prospective, Randomized and Double Blind Study.

• Status: Unknown status
• Trial end date: 2012-10-01
• Target enrollment: 0
• Participant gender: All

Summary

Recent reports suggest that most beneficial results of glutamine have been obtained with the parenteral administration of high doses of glutamine (0.35 g/Kg/d) and in some special group of patients, such as traumatic patients. Nevertheless total parenteral nutrition is not often used in critically ill patients.

The endovenous administration of the the dipeptide N(2)-L-alanyl-L-glutamine in trauma ICU patients can reduce the number of infections, ICU length of stay and mortality.

This benefit can be achieved independently the type of nutrition (enteral or parenteral nutrition), being a pharmaconutrient.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Hospital Universitari Son Dureta

Criteria

Inclusion Criteria:

• Moderate to severe trauma, as defined by an Injury Severity Score (ISS) > 10 points were included in the study.

• Traumatic patients who required enteral or parenteral nutrition during the first 48 hours after hospital admission

• Written informed consent

Exclusion Criteria:

• patients whose life expectancy was less than 5 days,

• who were allergic to glutamine,

• Patients included in any other trial

• Cirrhotic patients (Child C)

• Chronic renal failure